MedTrace Logo

The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy

NCT00113477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-07-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether supplements of Q10 and Selen are effective in reducing muscular adverse events (AE) in statin therapy.

Conditions

  • Statin Therapy

Interventions

DRUG

Q10

DRUG

Selen

Sponsors & Collaborators

  • Pharma Nord

    collaborator INDUSTRY

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Kjetil Retterstøl, MD · Lipidklinikken, Rikshospitalet-Radiumhospitalet HF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113477 on ClinicalTrials.gov